UPDATE: Signal Genetics Makes Improved Offer to Market Med BioGene Test
March 23, 2011
UPDATE: Signal Genetics Makes Improved Offer to Market Med BioGene Test
The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.